MedTrace Logo

Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery

NCT03424239 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-04-29

Study results available
· View outcomes & findings →

Summary

This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.

Conditions

  • Bariatric Surgery Candidate

Interventions

DRUG

Zoledronic Acid

5mg zoledronic acid

DIETARY_SUPPLEMENT

Calcium citrate + vitamin D

Chewable 500mg calcium citrate with 500 International Units (IU) Vitamin D3

DIETARY_SUPPLEMENT

Vitamin D3

1000IU Vitamin D3 gummy

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Elaine W Yu, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2020-01-01
Completion
2020-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03424239 on ClinicalTrials.gov